ATP2B3

Across TCGA pan-cancer cohorts, ATP2B3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP2B3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ATP2B3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP2B3 expression acts as an unfavorable survival marker.

ACC, ESCA, and PAAD are the cancer types where ATP2B3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	30	view →
ESCA	DFS	Median	All	0.164	0.509	.006	15	view →
PAAD	DFS	Median	All	0.141	0.508	.026	6	view →
PRAD	DFS	Median	All	0.174	0.888	<.001	6	view →
LIHC	OS	Median	All	0.188	0.669	.041	3	view →
HNSC	OS	Median	II,III,IV	0.250	0.673	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP2B3–ACC (DFS)

Open the ACC breakdown →